Syncope is a common problem experienced by up to 30% of people fainting and accounting for 3% of emergency room visits. Recurrent syncope is seen in 30-50% of patients and is associated with a poor quality of life that improves when the frequency of syncope is reduced. The majority of these patients suffer from neurally mediated syncope (NMS). The traditional model of NMS pathophysiology has focused on prior heightened sympathetic activation, followed by a sudden withdrawal of sympathetic tone and increase in vagal tone, with resultant vasodilation and bradycardia. Recent studies have found that the level of epinephrine rises PRIOR to syncope.
In Specific Aim #1, we will determine the contributions of epinephrine release and clearance to the elevated epinephrine levels. A beta adreneroreceptor agonist similar to epinephrine, isoproterenol is commonly used clincially to induce neurally mediated syncope. Beta- blocking drugs, in particular those with beta-2 antagonism (the receptor at which endogenous epinephrine promotes vasodilation), prevent tilt-induced syncope, and might prevent clinical syncope.
In Specific Aim #2, we will experimentally increase the epinephrine level and test whether this induces neurally mediated syncope. The response to epinephrine is likely to be substantially influenced by genetic heterogeneity in adrenoreceptors. Polymorphisms of these receptors might well account for inter-individual differences in sensitivity to the hemodynamic effects of epinephrine, and possibly in consequence, also susceptibility to syncope.
In Specific Aim #3, we will assess the susceptibility to syncope based upon common polymorphisms of the alpha-2B adrenoreceptor and the beta-2 adrenoreceptor. Using these Specific Aims, we will test the hypothesis that epinephrine or its receptors play an important role in the pathogenesis of neurally mediated syncope

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Wilde, David B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Brewster, Jordan A; Garland, Emily M; Biaggioni, Italo et al. (2012) Diurnal variability in orthostatic tachycardia: implications for the postural tachycardia syndrome. Clin Sci (Lond) 122:25-31
Peggs, Kiffany J; Nguyen, Hovan; Enayat, Diba et al. (2012) Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome. Int J Gynaecol Obstet 118:242-6
Mustafa, Hossam I; Fessel, Joshua P; Barwise, John et al. (2012) Dysautonomia: perioperative implications. Anesthesiology 116:205-15
Coffin, Samuel T; Black, Bonnie K; Biaggioni, Italo et al. (2012) Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm 9:1484-90
Mustafa, Hossam I; Raj, Satish R; Diedrich, André et al. (2012) Altered systemic hemodynamic and baroreflex response to angiotensin II in postural tachycardia syndrome. Circ Arrhythm Electrophysiol 5:173-80
Mustafa, Hossam I; Garland, Emily M; Biaggioni, Italo et al. (2011) Abnormalities of angiotensin regulation in postural tachycardia syndrome. Heart Rhythm 8:422-8
Hollenbeck, Ryan; Black, Bonnie K; Peltier, Amanda C et al. (2011) Long-term treatment with rituximab of autoimmune autonomic ganglionopathy in a patient with lymphoma. Arch Neurol 68:372-5
Bagai, Kanika; Song, Yanna; Ling, John F et al. (2011) Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med 7:204-10
Weiner, Justin B; Haddad, Elias V; Raj, Satish R (2010) Recovery following propofol-associated brugada electrocardiogram. Pacing Clin Electrophysiol 33:e39-42
McHugh, Julia; Keller, Nancy R; Appalsamy, Martin et al. (2010) Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control. Hypertension 55:1438-43

Showing the most recent 10 out of 38 publications